Compare ESI & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESI | SYRE |
|---|---|---|
| Founded | 1922 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 8.5B |
| IPO Year | 2014 | 2015 |
| Metric | ESI | SYRE |
|---|---|---|
| Price | $39.22 | $104.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $35.56 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 4.2M | 760.4K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $2,551,200,000.00 | N/A |
| Revenue This Year | $21.24 | N/A |
| Revenue Next Year | $7.34 | N/A |
| P/E Ratio | $168.74 | ★ N/A |
| Revenue Growth | ★ 3.84 | N/A |
| 52 Week Low | $22.86 | $14.51 |
| 52 Week High | $49.25 | $108.14 |
| Indicator | ESI | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 56.94 |
| Support Level | $38.39 | $92.37 |
| Resistance Level | $39.19 | $105.09 |
| Average True Range (ATR) | 1.18 | 5.39 |
| MACD | 0.39 | -0.38 |
| Stochastic Oscillator | 92.24 | 73.40 |
Element Solutions Inc is a specialty chemicals company whose businesses supply a broad range of solutions that enhance the performance of products people use every day. The company's reportable segments are Electronics and Industrial & Specialty. The Electronics segment, which generates maximum revenue, researches, formulates, and sells specialty chemicals and process technologies for all types of electronics hardware, from complex printed circuit board designs to semiconductor packaging. This segment's wet chemicals for metallization, surface treatments, and solderable finishes form the physical circuitry pathways, and its assembly materials, such as solder, pastes, fluxes, and adhesives, join those pathways together.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.